发布求助
文献互助 智能选刊 最新文献

Leukemia & Lymphoma最新文献

筛选
英文 中文
The landscape of clinical trials for heavily pretreated multiple myeloma: opportunity for more randomization? 重度预处理多发性骨髓瘤临床试验的前景：更多随机化的机会？
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-02-01 Epub Date: 2024-10-20 DOI: 10.1080/10428194.2024.2411625
Rohan Kapur, John McCarron, Sridevi Rajeeve, Ghulam Rehman Mohyuddin
{"title":"The landscape of clinical trials for heavily pretreated multiple myeloma: opportunity for more randomization?","authors":"Rohan Kapur, John McCarron, Sridevi Rajeeve, Ghulam Rehman Mohyuddin","doi":"10.1080/10428194.2024.2411625","DOIUrl":"10.1080/10428194.2024.2411625","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"355-357"},"PeriodicalIF":2.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142469027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Matching-adjusted indirect comparisons of zanubrutinib (MAGNOLIA, BGB-3111-AU-003) versus ibrutinib (PCYC-1121) and rituximab (CHRONOS-3) in relapsed/refractory marginal zone lymphoma. 在复发/难治性边缘区淋巴瘤中，扎鲁替尼 (MAGNOLIA, BGB-3111-AU-003) 与伊布替尼 (PCYC-1121) 和利妥昔单抗 (CHRONOS-3) 的匹配调整间接比较。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-02-01 Epub Date: 2024-10-24 DOI: 10.1080/10428194.2024.2416577
Catherine Thieblemont, Björn E Wahlin, Leyla Mohseninejad, Kaijun Wang, Ina Zhang, Sam Keeping, Keri Yang, Pier L Zinzani
{"title":"Matching-adjusted indirect comparisons of zanubrutinib (MAGNOLIA, BGB-3111-AU-003) versus ibrutinib (PCYC-1121) and rituximab (CHRONOS-3) in relapsed/refractory marginal zone lymphoma.","authors":"Catherine Thieblemont, Björn E Wahlin, Leyla Mohseninejad, Kaijun Wang, Ina Zhang, Sam Keeping, Keri Yang, Pier L Zinzani","doi":"10.1080/10428194.2024.2416577","DOIUrl":"10.1080/10428194.2024.2416577","url":null,"abstract":"<p><p>In the absence of head-to-head randomized trials, unanchored matching-adjusted indirect comparisons were conducted to estimate the relative efficacy of zanubrutinib versus ibrutinib and zanubrutinib versus rituximab in relapsed or refractory marginal zone lymphoma (MZL). Logistic propensity score models were used to estimate weights for the patient-level data from two phase II single-arm trials, MAGNOLIA and BGB-3111-AU-003, such that their characteristics matched the ibrutinib and rituximab aggregate-level data from PCYC-1121 and CHRONOS-3, respectively. The base case model for each comparison incorporated four key prognostic factors: prior lines of therapy, MZL subtype, response to prior therapy, and age. A sensitivity analysis incorporating additional prognostic factors was also conducted for the ibrutinib comparison. The impact of each covariate was explored <i>via</i> a leave-one-out analysis. Compared with ibrutinib and rituximab, zanubrutinib demonstrated significant benefits in terms of both overall response and progression-free survival in patients with previously treated MZL.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"240-249"},"PeriodicalIF":2.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142503151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Frailty measures in multiple myeloma: evaluating the impact on outcomes and quality-of-life in clinical trials and real-world practice. 多发性骨髓瘤中的虚弱测量方法：评估临床试验和实际操作对疗效和生活质量的影响。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-02-01 Epub Date: 2024-10-28 DOI: 10.1080/10428194.2024.2419375
Matthew J Pianko, Hira S Mian, Kelly L Schoenbeck, Tanya M Wildes
{"title":"Frailty measures in multiple myeloma: evaluating the impact on outcomes and quality-of-life in clinical trials and real-world practice.","authors":"Matthew J Pianko, Hira S Mian, Kelly L Schoenbeck, Tanya M Wildes","doi":"10.1080/10428194.2024.2419375","DOIUrl":"10.1080/10428194.2024.2419375","url":null,"abstract":"<p><p>Multiple myeloma is a hematologic malignancy that predominantly affects older individuals, in whom frailty is prevalent. Frailty is a clinical syndrome characterized by decreased reserve and increased vulnerability to stressors, leading to decreased functional capacity. Frailty is prevalent in older individuals and negatively impacts treatment outcomes. In this review, we summarize the tools and strategies used to assess frailty in patients with multiple myeloma, review data describing treatment outcomes in frail adults with multiple myeloma using clinical trial and real-world evidence and evaluate the potential relationship of frailty with quality of life and patient-reported outcomes during therapy for multiple myeloma. Frailty-adapted therapy for MM has the potential to improve treatment outcomes for older adults with myeloma.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"190-203"},"PeriodicalIF":2.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142503150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improvement in quality of life in MDS patients who become transfusion independent after treatment. 改善 MDS 患者的生活质量，使其在接受治疗后不再输血。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-02-01 Epub Date: 2024-11-09 DOI: 10.1080/10428194.2024.2422844
Bo A Wan, Shabbir M H Alibhai, Lisa Chodirker, Lee Mozessohn, Michelle Geddes, Nancy Zhu, Amy M Trottier, Eve St-Hilaire, Nicholas Finn, Brian Leber, Dina Khalaf, Grace Christou, Mitchell Sabloff, Heather A Leitch, April Shamy, Karen W L Yee, John Storring, Thomas J Nevill, Brett L Houston, Mohamed Elemary, Robert Delage, Anne Parmentier, Mohammad Siddiqui, Alexandre Mamedov, Liying Zhang, Rena Buckstein
{"title":"Improvement in quality of life in MDS patients who become transfusion independent after treatment.","authors":"Bo A Wan, Shabbir M H Alibhai, Lisa Chodirker, Lee Mozessohn, Michelle Geddes, Nancy Zhu, Amy M Trottier, Eve St-Hilaire, Nicholas Finn, Brian Leber, Dina Khalaf, Grace Christou, Mitchell Sabloff, Heather A Leitch, April Shamy, Karen W L Yee, John Storring, Thomas J Nevill, Brett L Houston, Mohamed Elemary, Robert Delage, Anne Parmentier, Mohammad Siddiqui, Alexandre Mamedov, Liying Zhang, Rena Buckstein","doi":"10.1080/10428194.2024.2422844","DOIUrl":"10.1080/10428194.2024.2422844","url":null,"abstract":"<p><p>Myelodysplastic syndromes (MDSs) treatment focuses on improving quality of life (QOL), affected by anemia and transfusion dependence (TD). Using the MDS-CAN registry, we studied how changes in transfusion status - TD to transfusion independence (TI) (group A), or vice versa (group B), and maintaining TD (group C) or TI (group D) - affected OS and QOL in 1120 MDS patients. Analysis showed superior OS for those remaining TI, poorer for those remaining TD, and intermediate for those with changes. Among 656 treated patients, group A (<i>n</i> = 54) showed improved QOL, with trends toward improved physical and social function scores. Group B (<i>n</i> = 151) experienced declines in global QOL measures after switching to TD, particularly in fatigue and physical, role, and social functioning. Group C had notable fatigue worsening, while group D showed milder declines across multiple QOL aspects. Achieving TI in MDS correlates with improved QOL, whereas reverting to TD more significantly worsens overall QOL and function scores.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"279-288"},"PeriodicalIF":2.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142622959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Blinatumomab use in patients with CD19 positive B-ALL and hepatic dysfunction. 在 CD19 阳性 B-ALL 和肝功能异常患者中使用 Blinatumomab。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-02-01 Epub Date: 2024-10-22 DOI: 10.1080/10428194.2024.2416018
Cynthia Fu, Dat Ngo, Jose Tinajero, Salman Otoukesh, Amandeep Salhotra
{"title":"Blinatumomab use in patients with CD19 positive B-ALL and hepatic dysfunction.","authors":"Cynthia Fu, Dat Ngo, Jose Tinajero, Salman Otoukesh, Amandeep Salhotra","doi":"10.1080/10428194.2024.2416018","DOIUrl":"10.1080/10428194.2024.2416018","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"320-324"},"PeriodicalIF":2.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142468924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Daratumumab-induced rhabdomyolysis in multiple myeloma: a rare case report. 达拉单抗诱发多发性骨髓瘤横纹肌溶解症：一例罕见病例报告。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-02-01 Epub Date: 2024-10-17 DOI: 10.1080/10428194.2024.2416578
Fang Luo, Yanxia Han, Qiao Ye
{"title":"Daratumumab-induced rhabdomyolysis in multiple myeloma: a rare case report.","authors":"Fang Luo, Yanxia Han, Qiao Ye","doi":"10.1080/10428194.2024.2416578","DOIUrl":"10.1080/10428194.2024.2416578","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"341-344"},"PeriodicalIF":2.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142469016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Single-cell sequencing applications in acute myeloid leukemia. 单细胞测序在急性髓性白血病中的应用
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-02-01 Epub Date: 2024-11-04 DOI: 10.1080/10428194.2024.2422833
Nicolas Lecornec, Matthieu Duchmann, Raphael Itzykson
{"title":"Single-cell sequencing applications in acute myeloid leukemia.","authors":"Nicolas Lecornec, Matthieu Duchmann, Raphael Itzykson","doi":"10.1080/10428194.2024.2422833","DOIUrl":"10.1080/10428194.2024.2422833","url":null,"abstract":"<p><p>Acute myeloid leukemia (AML) is a heterogeneous group of malignancies with poor prognosis. AML result from the proliferation of immature myeloid cells blocked at a variable stage of differentiation. Beyond inter-patient heterogeneity, AMLs are characterized by genetic and phenotypic intra-patient heterogeneity. Despite major advances in deciphering AML biology with bulk sequencing studies, pivotal questions remain unanswered. Analyses at the single-cell level could thus transform our understanding of these neoplasms. We review recent progresses in single-cell sequencing technologies from cell processing to bioinformatic pipelines. We next discuss how single-cell applications have helped understand the genetic and functional intra-leukemic heterogeneity, emphasizing aspects related to leukemic stem cells, clonal evolution and measurable residual disease (MRD) monitoring. We finally delineate how single-cell technologies could be implemented in routine clinical practice to improve patient management.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"175-189"},"PeriodicalIF":2.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142576309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HHV8-related Castleman disease presenting with nephrotic syndrome and pauci-immune glomerulonephritis. 与 HHV8 相关的 Castleman 病，表现为肾病综合征和贫免疫性肾小球肾炎。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-02-01 Epub Date: 2024-10-15 DOI: 10.1080/10428194.2024.2416023
Fanny Urbain, Sophie Ferlicot, Thierry Lazure, Tarek Bafakih, Sarah Mouawad, Arthur Lavigne, Paul-Albert Domnariu, Olivier Lambotte, Julien Dang
{"title":"HHV8-related Castleman disease presenting with nephrotic syndrome and pauci-immune glomerulonephritis.","authors":"Fanny Urbain, Sophie Ferlicot, Thierry Lazure, Tarek Bafakih, Sarah Mouawad, Arthur Lavigne, Paul-Albert Domnariu, Olivier Lambotte, Julien Dang","doi":"10.1080/10428194.2024.2416023","DOIUrl":"10.1080/10428194.2024.2416023","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"349-351"},"PeriodicalIF":2.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142469018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dose-adjusted direct oral anticoagulants (DOACs) in patients with acute leukemia: experience of a tertiary cancer care center. 急性白血病患者服用剂量调整型直接口服抗凝剂 (DOAC)：一家三级癌症护理中心的经验。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-02-01 Epub Date: 2024-10-07 DOI: 10.1080/10428194.2024.2411626
Sara A Bruner, Adam J DiPippo, Caitlin R Rausch
{"title":"Dose-adjusted direct oral anticoagulants (DOACs) in patients with acute leukemia: experience of a tertiary cancer care center.","authors":"Sara A Bruner, Adam J DiPippo, Caitlin R Rausch","doi":"10.1080/10428194.2024.2411626","DOIUrl":"10.1080/10428194.2024.2411626","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"352-354"},"PeriodicalIF":2.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142391526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Complete remission in a case of acute undifferentiated leukemia with novel combination therapy of FLAG-IDA and venetoclax. 使用 FLAG-IDA 和 venetoclax 的新型联合疗法使一例急性未分化白血病患者病情完全缓解。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-02-01 Epub Date: 2024-10-16 DOI: 10.1080/10428194.2024.2416573
Roma A Kankaria, Jeremy B Jones, Michael Zargari, Dylan Wrinn Alexander, Hannah Angle, Chelsie K Sievers, Sarah Profitt, Kateryna Fedorov, Claudio A Mosse, Somedeb Ball
{"title":"Complete remission in a case of acute undifferentiated leukemia with novel combination therapy of FLAG-IDA and venetoclax.","authors":"Roma A Kankaria, Jeremy B Jones, Michael Zargari, Dylan Wrinn Alexander, Hannah Angle, Chelsie K Sievers, Sarah Profitt, Kateryna Fedorov, Claudio A Mosse, Somedeb Ball","doi":"10.1080/10428194.2024.2416573","DOIUrl":"10.1080/10428194.2024.2416573","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"337-340"},"PeriodicalIF":2.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142468926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信